OBJECTIVES: Pharmacovigilance efforts for COVID-19 vaccines have largely focused on severe adverse events (AEs), while nonserious, yet distressing, AEs, such as oral AEs, remain underexamined. This study aimed to analyse oral AE reporting patterns in the German national pharmacovigilance database. METHODS: A retrospective analysis of individual case safety reports (ICSRs) from the Paul-Ehrlich-Institut (PEI) database was conducted for December 2020 to December 2023. The absolute reporting ratio was calculated as cases per 1000 ICSRs for each oral AE. Secondary analyses included: (1) cross-database comparisons with the U.S. Vaccine Adverse Event Reporting System (VAERS); (2) disproportionality analysis using a hybrid approach combining frequentist and Bayesian conditions to establish signals of disproportionate reporting (SDRs); (3) subgroup analyses based on demographic and vaccine-related factors; and (4) multivariable regression to adjust for potential confounders. RESULTS: Gustatory AEs, such as ageusia and dysgeusia; other oral sensory AEs, including oral paraesthesia and oral hypoaesthesia; and specific mucosal AEs, such as oral herpes and aphthous stomatitis, were the most frequently reported oral AEs in the PEI dataset. Cross-database analysis not only confirmed the prominence of gustatory and other sensory AEs but also highlighted differences, with VAERS reporting higher rates of swollen tongue and lip swelling. Disproportionality analysis identified 21 oral AEs as true SDRs. Female susceptibility was evident in several oral AEs, and age-stratified analysis revealed higher reporting among minors and seniors compared to middle-aged adults. Differences in oral AE reporting between mRNA and viral vector vaccines lacked a consistent pattern, and booster doses were associated with increased reporting of select oral AEs. CONCLUSIONS: Within the limitations of passive surveillance data, this study highlights the need for further research on oral AEs using self-controlled case-series designs for clinically significant events. Integrating oral AEs into vaccine safety monitoring could improve postmarketing surveillance, while validated AEs may warrant inclusion in product information for transparency.

Masaryk Centre for Global Health Department of Public Health Faculty of Medicine Masaryk University Brno Czech Republic; Department of Public Health Faculty of Medicine Masaryk University Brno Czech Republic

See more in PubMed

Oster M.E., Shay D.K., Su J.R., et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331–340. https://jamanetwork.com/journals/jama/fullarticle/2788346 [Accessed 13 February 2025]. Available from: PubMed PMC

Jaiswal V., Mukherjee D., Peng Ang S., et al. COVID-19 vaccine-associated myocarditis: analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. Int J Cardiol Heart Vasc. 2023;49 PubMed PMC

Shimabukuro T.T., Cole M., Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US – December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102. https://jamanetwork.com/journals/jama/fullarticle/2776557 [Accessed 24 May 2023]. Available from. PubMed PMC

Tsuchiya H., Mizogami M. Characteristics of oral adverse effects following COVID-19 vaccination and similarities with oral symptoms in COVID-19 patients: taste and saliva secretory disorders. Med Princ Pract. 2024;34(2):101–120. doi: 10.1159/000543182. [Accessed 14 February 2025] PubMed DOI PMC

Khazeei Tabari M.A., Najary S., Khadivi G., Yousefi M.J., Samieefar N., Abdollahimajd F. Oral lesions after COVID-19 vaccination: immune mechanisms and clinical approach. Infect Med. 2022;1(3):171–179. PubMed PMC

Riad A., Põld A., Kateeb E., Attia S. Oral adverse events following COVID-19 vaccination: analysis of VAERS reports. Front Public Health. 2022;10:2230. PubMed PMC

Riad A., Schulz-Weidner N., Dziedzic A., Howaldt H.P., Attia S. Oral side effects of COVID-19 vaccines in 32 European countries: analysis of EudraVigilance reports. J Med Virol. 2023;95(5) https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28771 [Accessed 24 May 2023]. Available from: PubMed DOI

Riad A., Issa J., Attia S., Dušek L., Klugar M. Oral adverse events following COVID-19 and influenza vaccination in Australia. Hum Vaccin Immunother. 2023;19(2) doi: 10.1080/21645515.2023.2253589. PubMed DOI PMC

Fusaroli M., Salvo F., Begaud B., et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585–599. https://pubmed.ncbi.nlm.nih.gov/38713347/ [Accessed 27 January 2025]. Available from: PubMed PMC

Paul-Ehrlich-Institute (PEI) Safety of COVID-19 Vaccines. 2024. Newsroom.https://www.pei.de/EN/newsroom/dossier/coronavirus/medicine-safety.html [Accessed 11 March 2025] Available from:

Paul-Ehrlich-Institut (PEI) Reports submitted to the Paul-Ehrlich-Institut of suspected side effects after the use of COVID-19 vaccines. 2024. Coronavirus and COVID-19.https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/reports-uaw/download-uaw-data-xls-2020-12-27-2023-12-31.html [Accessed 9 March 2025] 27 December 2020 - 31 December 2023, German only. Available from:

European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) – Module IX Addendum I – methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. 2017 [Accessed 14 February 2025]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf

Park G., Jung H., Heo S.J., Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life. 2020;10(8):138. https://www.mdpi.com/2075-1729/10/8/138/htm [Accessed 6 June 2024]. Available from: PubMed PMC

Cutroneo P.M., Sartori D., Tuccori M., et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3 https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2023.1323057/full [Accessed 14 February 2025]. Available from: DOI

Bundesministerium der Justiz (BMJ) Bundesministerium der Justiz; Germany: 2001. German Infection Protection Act (IfSG)https://www.gesetze-im-internet.de/ifsg/ [Accessed 9 March 2025]. Available from:

US-DHHS. VAERS data use guide. Vaccine Adverse Event Reporting System (VAERS). [Accessed 28 January 2025]. Available from: https://www.meddra.org/.

Lee Y., Min P., Lee S., Kim S.W. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35(18) https://synapse.koreamed.org/articles/1146024 [Accessed 14 February 2025]. Available from: PubMed PMC

VAC4EU. EMA-funded studies. [Accessed 14 February 2025]. Available from: https://vac4eu.org/ema-funded-studies/

Egbers T, Willame C, Belbachir L, et al. ACCESS-background rate of adverse events-definition –anosmia & ageusia [Accessed 10 March 2025]. Available from: https://zenodo.org/records/5236687

Liu Y.C.C., Munoz F.M., Izurieta H.S., et al. Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2023;41(11):1902–1910. PubMed

Bahri R.A., Abianeh F.E., Peisepar M., et al. Anosmia or ageusia following COVID-19 vaccination: a systematic review. Ear Nose Throat J. 2024;103(1_suppl):164S–170S. https://journals.sagepub.com/doi/full/10.1177/01455613241233098 [Accessed 14 February 2025]. Available from: PubMed DOI

Coelho P., Paula A., Martins I.V., et al. Combined central and peripheral demyelination after COVID-19 vaccination. J Neurol. 2022;269(9):4618–4622. PubMed PMC

Arabzadeh Bahri R., Esmaeilpur Abianeh F., Peisepar M., et al. Anosmia or ageusia following COVID-19 vaccination: a systematic review. Ear Nose Throat J. 2024;103(1_suppl):164S–170S. https://journals.sagepub.com/doi/10.1177/01455613241233098 [Accessed 10 March 2025]. Available from: PubMed DOI

European Medicines Agency (EMA). COVID-19 vaccine safety update COMIRNATY BioNTech Manufacturing GmbH. 2021 [Accessed 10 March 2025]. Available from:https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-6-october-2021_en.pdf

Riad A., Pokorná A., Klugarová J., et al. Side effects of mRNA-based COVID-19 vaccines among young adults (18–30 years old): an independent post-marketing study. Pharmaceuticals. 2021;14(10):1049. https://www.mdpi.com/1424-8247/14/10/1049 [Accessed 17 October 2021]. Available from: PubMed PMC

Shafiee A., Amini M.J., Arabzadeh Bahri R., et al. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):278. https://pmc.ncbi.nlm.nih.gov/articles/PMC10413536/ [Accessed 11 March 2025]. Available from: PubMed PMC

Boas RJEV, de Sousa M.S., Sousa L.F., et al. Oral herpes zoster following anti-COVID-19 vaccination: is there a relationship? Oral Surg Oral Med Oral Pathol Oral Radiol. 2024;137(6):e316.

Akpandak I., Miller D.C., Sun Y., Arnold B.F., Kelly J.D., Acharya NR. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw Open. 2022;5(11) https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798504 [Accessed 11 March 2025]. Available from: PubMed PMC

Pala E., Bayraktar M., Calp R. The potential association between herpes zoster and COVID-19 vaccination. Heliyon. 2024;10(4) https://www.cell.com/action/showFullText?pii=S2405844024017699 [Accessed 11 March 2025]. Available from: PubMed PMC

Wojcicki A.V., O’Flynn O’Brien K.L. Vulvar aphthous ulcer in an adolescent after Pfizer-BioNTech (BNT162b2) COVID-19 vaccination. J Pediatr Adolesc Gynecol. 2021;35(2):167. https://pmc.ncbi.nlm.nih.gov/articles/PMC8542512/ [Accessed 11 March 2025]. Available from: PubMed PMC

Maeda K., Yamashita D., Takenobu T. Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): a case report. J Stomatol Oral Maxillofac Surg. 2022;123(3):283–286. PubMed PMC

Kim H.K., Kim ME. A case of aphthous stomatitis in a healthy adult following COVID-19 vaccination: clinical reasoning. J Oral Med Pain. 2022;47(1):62–66. https://www.journalomp.org/journal/view.html?doi=10.14476/jomp.2022.47.1.62 [Accessed 11 March 2025]. Available from:

Deng J., Guo H., Kong R., Gao J. Case report: PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome with a novel TNFAIP3 mutation. Immun Inflamm Dis. 2024;13(3) https://www.authorea.com/doi/full/10.22541/au.172115263.32359099/v1?commit=1c5c1c9f78efbb70cecb7bd903a005bfde33541f [Accessed 11 March 2025]. Available from: PubMed DOI PMC

Gold M.S., Amarasinghe A., Greenhawt M., et al. Anaphylaxis: revision of the Brighton collaboration case definition. Vaccine. 2023;41(15):2605–2614. PubMed

Whitaker H.J., Hocine M.N., Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7–26. PubMed

Trifirò G., Coloma P.M., Rijnbeek P.R., et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551–561. https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12159 [Accessed 11 March 2025]. Available from: PubMed DOI

Bonaldo G., Noseda R., Ceschi A., Vaccheri A., Motola D. Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data. Sci Rep. 2020;10(1):1–9. https://www.nature.com/articles/s41598-020-70653-3 [Accessed 11 March 2025]. Available from: PubMed PMC

Anastassopoulou C., Boufidou F., Hatziantoniou S., Vasileiou K., Spanakis N., Tsakris A. Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination. Vaccine. 2023;41(48):7176–7182. PubMed

Montano D. Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. Front Public Health. 2022;9 www.frontiersin.org [Accessed 11 March 2025]. Available from: PubMed PMC

European Medicines Agency (EMA). Pharmacovigilance: overview. [Accessed 11 March 2025]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview

Statista . COVID-19-impfungen nach Geschlecht. 2024. Gesundheitszustand.https://de.statista.com/statistik/daten/studie/1477646/umfrage/menschen-in-deutschland-die-gegen-covid-19-geimpft-sind-nach-geschlecht/ [Accessed 11 March 2025] Available from:

Duijster J.W., Lieber T., Pacelli S., et al. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: a Dutch cohort study and review of the literature. Front Immunol. 2023;14 PubMed PMC

Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. 2017 [Accessed 16 November 2021];33:577–99. Available from: https://pubmed.ncbi.nlm.nih.gov/28992436/ PubMed

Rich J.T., Neely J.G., Paniello R.C., Voelker C.C.J., Nussenbaum B., Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010;143(3):331. https://pmc.ncbi.nlm.nih.gov/articles/PMC3932959/ [Accessed 11 March 2025]. Available from: PubMed PMC